Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy.

Experimental neurology - 1 Jul 2008

El-Khodor Bassem F, Edgar Nicole, Chen Angela, Winberg Margaret L, Joyce Cynthia, Brunner Daniela, Suárez-Fariñas Mayte, Heyes Melvyn P

Abstract excerpt

Spinal muscular atrophy (SMA) is characterized by selective loss of alpha-motor neurons and is caused by homozygous loss or mutation in the survival motor neuron (SMN1) gene. Loss of SMN1 is partially compensated by the copy gene, SMN2. Currently, there are no specific treatments for SMA. Key features of SMA are modeled in mice by deletion of murine Smn, and insertion of both full length human SMN2 gene and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclic AMP Response Element-Binding Protein
Share to Drug Evaluation, Preclinical

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Movement Disorders

Share to Research Design

Share to SMN Complex Proteins

Share to Spinal Muscular Atrophies of Childhood

Share to Survival of Motor Neuron 1 Protein

Share to Survival of Motor Neuron 2 Protein

Source

Identifiers

PMID: 18455159
DOI: 10.1016/j.expneurol.2008.02.025

Genes

SMN2
SMN1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy.PMID 18455159Read ↗

Abnormal motor phenotype in the SMNDelta7 mouse model of spinal muscular atrophy.Semantic proximity Read ↗

Assays for the Identification and Prioritization of Drug Candidates for Spinal Muscular AtrophySemantic proximity Read ↗

Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy.Semantic proximity Read ↗

Current advances in drug development in spinal muscular atrophy.Semantic proximity Read ↗

Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium.Semantic proximity Read ↗

Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal modelSemantic proximity Read ↗

Nusinersen rescues taurine deficiency in severe Spinal Muscular AtrophySemantic proximity Read ↗

Drosophila SMN2 minigene reporter model identifies moxifloxacin as a candidate therapy for SMASemantic proximity Read ↗

Prediction of death in the SMNΔ7 mouse model of spinal muscular atrophy: insight into disease stage and progression.Semantic proximity Read ↗

A Novel System for Spinal Muscular Atrophy Screening in Newborns: Japanese Pilot StudySemantic proximity Read ↗

Subcutaneous administration of TC007 reduces disease severity in an animal model of SMASemantic proximity Read ↗

Newborn and carrier screening for spinal muscular atrophy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.